ViziLite Plus with TBlue is now available to 55% of the people in the western and eastern EU-member countries, said Zila.
Zila has previously announced that it had selected distributors for the product in the UK, Ireland, Greece and Cyprus.
ViziLite Plus with TBlue, Zila’s product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer, according to Zila.
David Bethune, chairman and CEO of Zila, said: “The marketing of ViziLite Plus in Spain, France, Germany and Portugal provides a solid core of countries in Europe with an important new oral cancer screening tool. We believe Dentaid’s direct selling force will communicate the unique attributes of ViziLite Plus to the dental healthcare community and build it into a leading brand in these markets.”